Peptide Reference
Semaglutide
Semaglutide Peptide
A GLP-1 receptor agonist peptide that regulates appetite and blood sugar. The active pharmaceutical ingredient in Ozempic and Wegovy, also available as research peptide.
Status
approved
Category
weight loss
Typical cost
$900-1400/month (brand), $149-400/month (compounded)
Mechanism
Mimics GLP-1 hormone, stimulating insulin secretion in response to glucose, suppressing glucagon, delaying gastric emptying, and acting on hypothalamic appetite centers to reduce hunger.
Potential benefits
- Significant weight loss
- Improved glycemic control
- Reduced cardiovascular risk
- Appetite suppression
- Better portion control
- Sustained energy
Reported side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Injection site reactions
- Gallbladder issues
- Pancreatitis risk
Common dosing references
subcutaneous
0.25-2.4mg · Weekly
Ongoing
Research notes
STEP 1 Trial - Semaglutide 2.4mg
2021
Average 14.9% weight loss at 68 weeks in adults with obesity
SUSTAIN 6 - Cardiovascular outcomes
2016
Significant reduction in major adverse cardiovascular events in type 2 diabetes patients
Regulatory and sourcing notes
FDA-approved (Ozempic for diabetes, Wegovy for weight loss). Also available as research peptide from compounding pharmacies (503A/503B).
Prescription required for brand (Ozempic/Wegovy). Compounded versions available during shortages. Verify 503B pharmacy accreditation.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides